Globus Medical, Pan American Silver, Kinross Gold Flagged as Under-Covered Large-Caps

A recent market analysis identified three large-capitalization stocks—Globus Medical (GMED), Pan American Silver (PAAS), and Kinross Gold (KGC)—that exhibit strong fundamentals but receive significantly less attention from Wall Street analysts than their peers, potentially creating a valuation gap.

The Analyst Coverage Gap

According to an August 28 report from Investing.com, the primary indicator of these companies being “under the radar” is their thin analyst coverage. While large-cap stocks are typically followed by 20 to 30 analysts, these companies have far fewer:

• Globus Medical (GMED): 13 analysts
• Kinross Gold (KGC): 10 analysts
• Pan American Silver (PAAS): 8 analysts

The report suggests this limited institutional focus may mean the companies' recent performance and future prospects are not fully priced into their stocks.

Performance vs. Valuation

Ad

The analysis highlights a disconnect between the companies' recent financial results and their stock performance over the past six months. Globus Medical reported 51.5% earnings per share (EPS) growth and 19.7% revenue growth, yet its stock has declined 6.9% over the period. The medical device firm trades at a forward price-to-earnings (P/E) ratio of 16.1x.

Similarly, the two precious metals producers have posted significant growth, with Pan American Silver reporting 133% EPS growth and Kinross Gold delivering 112% EPS growth. Despite this, their stocks are down 18.1% and 7.4% respectively over the last six months, according to the report's data.

Financial Health and Associated Risks

The report also points to several indicators of financial strength. Kinross Gold holds a perfect Piotroski Score of 9, a top mark for financial health, while Globus Medical operates with a low debt-to-equity ratio of 2.3% and maintains gross margins of 69%. Pan American Silver has a 17-year history of paying dividends.

However, potential risks were also noted. Both Pan American Silver and Kinross Gold carry moderate debt levels and are subject to the inherent volatility of commodity prices. The report also mentioned that Kinross Gold's Relative Strength Index (RSI) suggests the stock may be in overbought territory in the short term, while Globus Medical is a pure growth play that does not pay a dividend.